Search results
Vaccine makers receive stock boost after third human bird flu case in US
Newsweek· 18 hours agoShares in some companies that produce vaccines have seen stock boosts following a small number of...
The Highest Paid CEOs of 2023
The Wall Street Journal· 3 days agoModerna reported total pay of $17.1 million for CEO Stéphane Bancel last year, including $12.5 million in stock and option awards. The value of those...
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Zacks via Yahoo Finance· 7 days agoNVAX, Sanofi SNY, Fulcrum Therapeutics, Inc. FULC, Moderna, Inc. MRNA and Bristol Myers BMY. Here...
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Benzinga· 7 days agoModerna Inc MRNA has reportedly achieved a significant victory at the European Patent Office (EPO)...
Could Novavax Become the Next Moderna? | The Motley Fool
The Motley Fool· 7 days agoModerna fared well, dominating the vaccine market along with big pharma rival Pfizer, and bringing...
Moderna wins COVID shot patent case against Pfizer-BioNTech in Europe
Reuters· 7 days agoModerna said on Friday the European Patent Office had upheld the validity of one of the company's...
Bird Flu Cases Spur Retail Trader Rush Into Vaccine Stocks
Bloomberg via Yahoo Finance· 1 day ago(Bloomberg) -- Mounting cases of bird flu in humans is luring the day trading crowd to snap up stock...
Moderna Inc (MRNA)'s Uncertain Future: Understanding the Barrier
Guru Focus· 4 days agoLong-established in the Biotechnology industry, Moderna Inc (MRNA, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth ...
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks via Yahoo Finance· 16 hours agoPerformance The Nasdaq Biotechnology Index has moved up 0.83% in the past five trading sessions and ...
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
The Motley Fool via AOL· 5 days agoThe company's new strategy has many moving parts, many of which could go wrong, and if they do, the stock will sink. Novavax is pursuing full approval for Nuvaxovid in the ...
